Core Viewpoint - DJS Law Group is investigating Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding a clinical study [1][2]. Investigation Details - The investigation centers on Larimar's September 29, 2025 announcement of an open-label study involving daily subcutaneous injections of Nomlabofusp for Friedreich's Ataxia, which was presented as having positive results despite severe allergic reactions experienced by multiple participants [2]. - Following the release of this information, Larimar's shares experienced a significant decline of 33.66% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Larimar Therapeutics, Inc. following the announcement of adverse reactions in a clinical study, which led to a significant drop in the company's stock price [1][2]. Summary by Sections Investigation Details - The investigation centers on whether Larimar Therapeutics made false or misleading statements or failed to disclose critical information to investors [2]. - On September 29, 2025, Larimar reported data from an ongoing study of Nomlabofusp for Friedreich's Ataxia, claiming positive results while also revealing that seven participants experienced severe allergic reactions or anaphylaxis [2]. Market Reaction - Following the announcement of the study results and the adverse reactions, Larimar's shares fell by over 33.6% on the same day [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Larimar Therapeutics, Inc. following a significant stock price drop after the release of clinical trial data [1] Group 1: Company Overview - Larimar Therapeutics, Inc. is publicly traded on NASDAQ under the ticker LRMR [1] - The company is currently conducting a long-term open-label study on Nomlabofusp for treating Friedreich's Ataxia [1] Group 2: Recent Developments - On September 29, 2025, Larimar announced "positive" data from its ongoing study, but also reported seven cases of anaphylaxis among participants [1] - Following the announcement, Larimar's stock price decreased by $1.72, representing a 33.66% decline, closing at $3.38 per share [1]